Leerink Partners Downgrades Viracta Therapeutics to Market Perform, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has downgraded Viracta Therapeutics (NASDAQ:VIRX) from Outperform to Market Perform and lowered the price target from $5 to $3.
August 16, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Leerink Partners downgraded Viracta Therapeutics from Outperform to Market Perform and reduced the price target from $5 to $3.
The downgrade from Outperform to Market Perform and the significant reduction in the price target from $5 to $3 by Leerink Partners is likely to negatively impact investor sentiment and the short-term stock price of Viracta Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100